secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2025-08-19T23:59:59+00:00
Accession:  0000950170-25-109932
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra receives FDA Fast Track Designation for ADX-2191 in retinitis pigmentosa
--------------------------------------------------------------------------------

- FDA granted Fast Track Designation for ADX-2191 (methotrexate intravitreal injection) for retinitis pigmentosa.
- No approved therapy exists for most forms of retinitis pigmentosa, which affects over 1 million people worldwide.
- Fast Track complements prior Orphan Drug Designation; may allow rolling review or priority/accelerated approval.
- Phase 2/3 trial of ADX-2191 in retinitis pigmentosa expected to start in 2025.
- Phase 2 results (2023) showed improvements from baseline in retinal sensitivity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000095017025109932/0000950170-25-109932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000095017025109932/aldx-20250819.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-109932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer